Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - sunitinib malate, quantity: 66.825 mg (equivalent: sunitinib, qty 50 mg) - capsule, hard - excipient ingredients: gelatin; mannitol; magnesium stearate; titanium dioxide; purified water; croscarmellose sodium; povidone; iron oxide yellow; iron oxide black; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - sunitinib sun is indicated for:,? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - sunitinib malate, quantity: 50.119 mg (equivalent: sunitinib, qty 37.5 mg) - capsule, hard - excipient ingredients: gelatin; mannitol; magnesium stearate; titanium dioxide; purified water; croscarmellose sodium; povidone; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - sunitinib sun is indicated for:,? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - sunitinib malate, quantity: 33.413 mg (equivalent: sunitinib, qty 25 mg) - capsule, hard - excipient ingredients: gelatin; mannitol; magnesium stearate; iron oxide red; titanium dioxide; purified water; croscarmellose sodium; povidone; iron oxide yellow; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - sunitinib sun is indicated for:,? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - sunitinib malate, quantity: 16.706 mg (equivalent: sunitinib, qty 12.5 mg) - capsule, hard - excipient ingredients: gelatin; mannitol; magnesium stearate; iron oxide red; titanium dioxide; purified water; croscarmellose sodium; povidone; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - sunitinib sun is indicated for:,? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Canada - English - Health Canada

natco pharma (canada) inc - sunitinib (sunitinib malate) - capsule - 50mg - sunitinib (sunitinib malate) 50mg

Malta - English - Medicines Authority

aqvida gmbh kaiser-wilhelm-str 89, 20355 hamburg, germany - sunitinib - hard capsule - sunitinib 25 mg - antineoplastic agents

Malta - English - Medicines Authority

aqvida gmbh kaiser-wilhelm-str 89, 20355 hamburg, germany - sunitinib - hard capsule - sunitinib 37.5 mg - antineoplastic agents

Malta - English - Medicines Authority

aqvida gmbh kaiser-wilhelm-str 89, 20355 hamburg, germany - sunitinib - hard capsule - sunitinib 50 mg - antineoplastic agents

Malta - English - Medicines Authority

aqvida gmbh kaiser-wilhelm-str 89, 20355 hamburg, germany - sunitinib - hard capsule - sunitinib 12.5 mg - antineoplastic agents

Malta - English - Medicines Authority

sandoz pharmaceuticals d.d. verovškova ulica 57, si-1000 ljubljana, slovenia - sunitinib - hard capsule - sunitinib 12.5 mg - antineoplastic agents